{"meta":{"query_hash":"53a01e2d7de3","filters":{"venue":"Canadian oncology today."},"cohort_total":23,"direct_labels_cover":0,"predictions_cover":23,"exported":23,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/53a01e2d7de3","api":"https://metacan.xera.ac/api/v1/cohort?venue=Canadian+oncology+today."},"results":[{"id":"W4403604639","doi":"10.58931/cot.2024.1223","title":"Survivorship Issues in Testicular Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; National Institutes of Health; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Survivorship curve; Testicular cancer; Cancer survivorship; Cancer; Medicine; Gerontology; Psychology; Internal medicine","score_opus":0.024069372259093218,"score_gpt":0.361931690930239,"score_spread":0.3378623186711458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403604639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8596139,0.08357126,0.0000058618493,0.036431644,0.0011401955,0.00059225014,0.00014163902,0.0001504672,0.018352812],"genre_scores_gemma":[0.9944487,0.00030249034,0.00015282104,0.0015649135,0.00019196347,0.00009157548,0.000051866868,0.000025401203,0.003170249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991196,0.00004101418,0.00013440287,0.00025986892,0.00008135028,0.0003637996],"domain_scores_gemma":[0.9991297,0.000084449515,0.000011960793,0.00016630934,0.000032953332,0.0005745847],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008698563,0.00012043257,0.00022503578,0.00026251172,0.00003399583,0.000019053155,0.000052194526,0.00013815405,0.001222064],"category_scores_gemma":[0.00013811358,0.00010513574,0.000063162704,0.00029572909,0.000060546452,0.00003745665,0.000009076506,0.00016204733,0.0003032275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003590216,0.00018418772,0.8297837,0.0001905492,0.00026684778,0.038695242,0.00043517025,0.00002646971,0.00010507233,0.0032526606,0.026918119,0.1001061],"study_design_scores_gemma":[0.00072308176,0.000248604,0.5258355,0.0003604278,0.00024045425,0.00017792055,0.00007300819,0.00051759137,0.00004188184,0.00063944183,0.47098684,0.00015521856],"about_ca_topic_score_codex":0.38995215,"about_ca_topic_score_gemma":0.70299315,"teacher_disagreement_score":0.44406873,"about_ca_system_score_codex":0.0012481106,"about_ca_system_score_gemma":0.0027565705,"threshold_uncertainty_score":0.99969095},"labels":[],"label_agreement":null},{"id":"W4403604711","doi":"10.58931/cot.2024.1221","title":"Current Uses and Pitfalls of Liquid Biopsy in NSCLC","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation; American Society of Clinical Oncology; International Association for the Study of Lung Cancer","keywords":"Liquid biopsy; Biopsy; Current (fluid); Medicine; Radiology; Medical physics; Internal medicine; Cancer; Physics","score_opus":0.011203312767678752,"score_gpt":0.2805186838250549,"score_spread":0.26931537105737613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403604711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961873,0.033910863,0.00003307758,0.00090173504,0.0006444664,0.00011460089,0.00013624916,0.0000040209343,0.0023820088],"genre_scores_gemma":[0.9958143,0.0034295474,0.000112530324,0.0003176856,0.00017448641,0.0000144712285,0.000045783047,0.000013639635,0.00007750961],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99934673,0.000023393808,0.00015578757,0.00023055568,0.000029345136,0.000214174],"domain_scores_gemma":[0.9995979,0.000035384226,0.000021447293,0.00013916021,0.00002777292,0.00017835559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109637374,0.00008805425,0.00013025934,0.00014229763,0.000019484445,0.000011772253,0.0000869514,0.00014254174,0.000031498043],"category_scores_gemma":[0.00007605198,0.000093641254,0.00003319069,0.00009215556,0.0001061645,0.0000019101515,0.000041035426,0.00008813168,0.000006990256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005289649,0.0003029203,0.052063007,0.00057074614,0.0003018864,0.000899676,0.0016285869,0.00017153482,0.42214146,0.030462278,0.12433139,0.36659753],"study_design_scores_gemma":[0.00033576335,0.0005705769,0.0076908055,0.000077356206,0.000018705749,0.000048866856,0.000060654944,0.000044604443,0.007885893,0.00020831171,0.9828786,0.00017983149],"about_ca_topic_score_codex":0.009301424,"about_ca_topic_score_gemma":0.1712963,"teacher_disagreement_score":0.8585472,"about_ca_system_score_codex":0.00011143054,"about_ca_system_score_gemma":0.0013573961,"threshold_uncertainty_score":0.99729574},"labels":[],"label_agreement":null},{"id":"W4403604822","doi":"10.58931/cot.2024.1224","title":"An Evolving Paradigm in Borderline Resectable and Locally Advanced Pancreatic Cancer: Current Strategies and Opportunities for the Future","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Current (fluid); Medicine; Pancreatic cancer; Cancer; Intensive care medicine; Internal medicine; Engineering; Electrical engineering","score_opus":0.05318225327021265,"score_gpt":0.38340732239535136,"score_spread":0.3302250691251387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403604822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6087474,0.32248345,0.0003274531,0.06272156,0.00064652204,0.0017559881,0.00011721765,0.000055194418,0.0031452375],"genre_scores_gemma":[0.94869757,0.04783458,0.0004362182,0.00095260364,0.0005330324,0.000669841,0.00004661846,0.00003046192,0.0007990605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986568,0.000110231405,0.00024964623,0.00033313117,0.00010268577,0.0005474873],"domain_scores_gemma":[0.9985064,0.00066201534,0.000031028125,0.00020950763,0.0000931337,0.0004978649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000596714,0.0001672346,0.00046553512,0.00026853874,0.0002236961,0.00010307308,0.000104245584,0.00018619718,0.00014447089],"category_scores_gemma":[0.000086896995,0.000120322235,0.00002874788,0.00015865164,0.0003796928,0.0002589325,0.000019795649,0.0004278253,0.0000012393649],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004666707,0.00008488357,0.05015236,0.0010961486,0.0002571245,0.0009072051,0.00291014,0.0000378649,0.00014970062,0.031657673,0.010733737,0.9015465],"study_design_scores_gemma":[0.002986084,0.002313958,0.115499936,0.00093716104,0.00048691742,0.00030727658,0.021806601,0.05900733,0.000007350494,0.004823419,0.7914844,0.00033955055],"about_ca_topic_score_codex":0.018328324,"about_ca_topic_score_gemma":0.46280083,"teacher_disagreement_score":0.9012069,"about_ca_system_score_codex":0.00055057905,"about_ca_system_score_gemma":0.008306015,"threshold_uncertainty_score":0.99731594},"labels":[],"label_agreement":null},{"id":"W4403604899","doi":"10.58931/cot.2024.1222","title":"From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Breast cancer; Medicine; New horizons; Cancer; General surgery; Internal medicine; Engineering","score_opus":0.027025459900487908,"score_gpt":0.37526584115896766,"score_spread":0.3482403812584798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403604899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82215375,0.009070018,0.000008639941,0.12869881,0.0006870753,0.0011802454,0.0011001034,0.000028463304,0.037072882],"genre_scores_gemma":[0.9927078,0.0014957119,0.0003824842,0.0019736711,0.00032748727,0.00031847655,0.000029695042,0.00002781641,0.0027368772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988142,0.00007454814,0.00019344219,0.00030873768,0.00017185403,0.00043719937],"domain_scores_gemma":[0.9991122,0.00014563592,0.000014942119,0.00029457515,0.00004122237,0.00039142536],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035085593,0.00011534249,0.00026365143,0.00029948165,0.00004694483,0.000025399593,0.00017621319,0.00012006081,0.0012828187],"category_scores_gemma":[0.0000136246235,0.00008796586,0.000026303172,0.0005880351,0.00012280556,0.000045417135,0.000039909886,0.00029910335,0.00004805498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000176816,0.000119165576,0.027558224,0.00056118524,0.00038276947,0.0060503776,0.0049175085,0.000016923339,0.0006117059,0.002112479,0.2517593,0.70573354],"study_design_scores_gemma":[0.0006143341,0.00032489892,0.194177,0.00086714845,0.0001440687,0.00018284432,0.0028778417,0.00009093031,0.00012050428,0.00025552747,0.8002143,0.00013061796],"about_ca_topic_score_codex":0.55889714,"about_ca_topic_score_gemma":0.6270247,"teacher_disagreement_score":0.70560294,"about_ca_system_score_codex":0.0012354214,"about_ca_system_score_gemma":0.0018487669,"threshold_uncertainty_score":0.99963015},"labels":[],"label_agreement":null},{"id":"W4403604925","doi":"10.58931/cot.2024.1220","title":"Current and Emerging Treatment Options for HER2‑Positive Gastroesophageal Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Current (fluid); Internal medicine; Intensive care medicine; Oncology; Oceanography; Geology","score_opus":0.0256144487643433,"score_gpt":0.3538786207820933,"score_spread":0.32826417201775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403604925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5025735,0.18210815,0.0025812476,0.26152232,0.013764062,0.007590855,0.00209668,0.0005174199,0.027245771],"genre_scores_gemma":[0.9810179,0.0041382993,0.0008459105,0.0016993202,0.001239479,0.0007725443,0.0001804368,0.000042657262,0.010063446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991707,0.000015564565,0.00013179671,0.0002661956,0.00005155096,0.00036415822],"domain_scores_gemma":[0.9994098,0.00006523264,0.000019050625,0.000092635484,0.000037124777,0.00037615316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007033913,0.0001321752,0.00022737967,0.00026968334,0.0001206281,0.000027257898,0.00003397791,0.000055697845,0.00032575676],"category_scores_gemma":[0.0000112668795,0.00011548254,0.00008301079,0.00014377202,0.000059188988,0.000047934234,0.000011419333,0.000095455536,0.000015536945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005729803,0.00004796347,0.019032387,0.0001446383,0.00037948033,0.00040007176,0.0008512862,0.000016923323,0.000026321366,0.0048585506,0.0628183,0.91136676],"study_design_scores_gemma":[0.0011901662,0.0007526753,0.04875545,0.00012078413,0.00049345667,0.000041177802,0.00021298652,0.00080216955,0.00002588099,0.00012175054,0.94738364,0.00009983704],"about_ca_topic_score_codex":0.017385332,"about_ca_topic_score_gemma":0.14824353,"teacher_disagreement_score":0.9112669,"about_ca_system_score_codex":0.0019849495,"about_ca_system_score_gemma":0.001173373,"threshold_uncertainty_score":0.989158},"labels":[],"label_agreement":null},{"id":"W4403961654","doi":"10.58931/cot.2024.1326","title":"Prostate-specific Membrane Antigen (PSMA): A Diagnostic and Therapeutic Target in Advanced Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Glutamate carboxypeptidase II; Prostate cancer; Prostate-specific antigen; Medicine; Prostate; Antigen; Cancer; Cancer research; Oncology; Internal medicine; Immunology","score_opus":0.021559119780432432,"score_gpt":0.32790311552643636,"score_spread":0.3063439957460039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403961654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8268143,0.13905956,0.0000019507152,0.026853604,0.0006356152,0.0020617559,0.00020567125,0.00008534348,0.0042822263],"genre_scores_gemma":[0.95544267,0.036416654,0.00014547101,0.0011586227,0.00015082759,0.0007451629,0.000109945126,0.00006436496,0.00576627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979551,0.00009065704,0.0002910903,0.0005956121,0.00017446258,0.00089307176],"domain_scores_gemma":[0.99866796,0.00030452033,0.000031031203,0.0002295346,0.00008111794,0.00068585586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026846016,0.0002574225,0.00044984298,0.00058216153,0.00012123734,0.00005572569,0.00009814416,0.00020259152,0.0007093151],"category_scores_gemma":[0.000060980026,0.00020998594,0.000056311845,0.0006095347,0.00029887346,0.0001096257,0.00002933975,0.0004997146,0.000083527244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013901044,0.00026635558,0.38132757,0.0009856707,0.0005090567,0.02155863,0.010381556,0.000104091596,0.011484147,0.001072768,0.0130333835,0.55788666],"study_design_scores_gemma":[0.0040063597,0.0010644016,0.11235884,0.0007717273,0.00006726721,0.00020253443,0.0006391653,0.00042021638,0.0023191036,0.00069984875,0.87707454,0.0003759835],"about_ca_topic_score_codex":0.014050164,"about_ca_topic_score_gemma":0.088143766,"teacher_disagreement_score":0.86404115,"about_ca_system_score_codex":0.0018040271,"about_ca_system_score_gemma":0.0038645049,"threshold_uncertainty_score":0.9925154},"labels":[],"label_agreement":null},{"id":"W4403961830","doi":"10.58931/cot.2024.1329","title":"Antibody-drug Conjugates in The Management of Advanced Urothelial Carcinoma","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Urothelial carcinoma; Antibody; Drug; Antibody-drug conjugate; Medicine; Conjugate; Carcinoma; Cancer research; Internal medicine; Pharmacology; Immunology; Monoclonal antibody; Cancer; Bladder cancer","score_opus":0.014360824321639591,"score_gpt":0.31596838758125917,"score_spread":0.30160756325961957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403961830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78113055,0.0072846925,0.000009533332,0.013235041,0.000918451,0.0012176693,0.00013201566,0.000036801073,0.19603527],"genre_scores_gemma":[0.995291,0.00031445822,0.00018722111,0.0020208168,0.00010793195,0.000082594255,0.000051715033,0.000019634357,0.001924631],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906063,0.000056078283,0.00021011167,0.00023671988,0.000119738426,0.00031671175],"domain_scores_gemma":[0.9994892,0.00005898025,0.000022289178,0.00024468658,0.00002602657,0.00015884245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017550534,0.00012809648,0.00024807322,0.00019990225,0.000042508942,0.000010811086,0.00014113326,0.000076264885,0.00033331788],"category_scores_gemma":[0.0000053375743,0.00009155638,0.00007305276,0.00028041043,0.00010972982,0.000041358675,0.000013804819,0.00017802812,0.00007539504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001687536,0.0011086551,0.19194709,0.003772584,0.002453358,0.062222376,0.031456817,0.000065246655,0.009273951,0.06290098,0.054390058,0.57872134],"study_design_scores_gemma":[0.0048630578,0.0011585773,0.2205006,0.0006899194,0.0005289402,0.00034959707,0.004367403,0.00010128461,0.0014609686,0.0011804736,0.764527,0.00027215312],"about_ca_topic_score_codex":0.027423816,"about_ca_topic_score_gemma":0.05376488,"teacher_disagreement_score":0.71013695,"about_ca_system_score_codex":0.00044855886,"about_ca_system_score_gemma":0.0010316917,"threshold_uncertainty_score":0.97905266},"labels":[],"label_agreement":null},{"id":"W4403961868","doi":"10.58931/cot.2024.1328","title":"Tailored Approaches and Patient-centered Care: The Current Landscape of Neoadjuvant Therapy in Rectal Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Colorectal cancer; Medicine; Current (fluid); Neoadjuvant therapy; Oncology; Cancer; Intensive care medicine; General surgery; Internal medicine; Breast cancer; Engineering","score_opus":0.04670660681887358,"score_gpt":0.31028578139431917,"score_spread":0.2635791745754456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403961868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.889343,0.09818085,3.667309e-7,0.0048020636,0.0007261655,0.0006668453,0.000075857766,0.00001794574,0.0061868895],"genre_scores_gemma":[0.99686784,0.0024248655,0.00001451902,0.00029477334,0.00007843401,0.00021902008,0.000031228064,0.000018224806,0.00005107251],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990065,0.000083011044,0.00021781636,0.00028503977,0.00010836106,0.00029924407],"domain_scores_gemma":[0.99942636,0.00010147946,0.000036905538,0.00015765865,0.0000379516,0.00023965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007159258,0.0001438796,0.00031470315,0.0001876875,0.00004074324,0.000012335785,0.000071309,0.00009777031,0.00018663133],"category_scores_gemma":[0.000022931852,0.00009348559,0.00006762493,0.0002935091,0.00014441524,0.00003336425,0.000024009481,0.00028096075,0.00000504406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003112163,0.00005972734,0.06238026,0.000057119996,0.00009412922,0.00025107368,0.0045796367,0.000004248757,0.000033785273,0.000072319934,0.001809665,0.9303468],"study_design_scores_gemma":[0.0049345205,0.0034334452,0.2821186,0.0006340375,0.0001458127,0.00013198965,0.002454573,0.0007977409,0.00054619386,0.00014602339,0.7043486,0.0003084449],"about_ca_topic_score_codex":0.020014377,"about_ca_topic_score_gemma":0.20684336,"teacher_disagreement_score":0.9300384,"about_ca_system_score_codex":0.0008806856,"about_ca_system_score_gemma":0.0015324402,"threshold_uncertainty_score":0.9865114},"labels":[],"label_agreement":null},{"id":"W4403961907","doi":"10.58931/cot.2024.1325","title":"First-line Treatment Selection for Advanced Hepatocellular Carcinoma","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Hepatocellular carcinoma; Selection (genetic algorithm); Line (geometry); Oncology; Medicine; Internal medicine; Computer science; Artificial intelligence; Mathematics","score_opus":0.05903454439788217,"score_gpt":0.2902703179108537,"score_spread":0.23123577351297156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403961907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96924233,0.007579195,0.0005219028,0.012938339,0.00087323884,0.0023665947,0.00013335473,0.00021637535,0.0061286716],"genre_scores_gemma":[0.9880986,0.0002426253,0.0014337981,0.00058504986,0.00052337843,0.0009376385,0.00039205002,0.00006635554,0.0077204644],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849075,0.000038010417,0.0002675896,0.00050580944,0.000092001304,0.0006058257],"domain_scores_gemma":[0.9987838,0.00015050771,0.00003204675,0.00021902974,0.000102603146,0.00071195874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013271683,0.0002763061,0.0004314401,0.0003981058,0.00022642378,0.000031529675,0.00006240043,0.00030801925,0.0005293499],"category_scores_gemma":[0.000039459424,0.00024255169,0.00028194886,0.00032730715,0.00005753095,0.00007522168,0.000007383134,0.0001393119,0.00020815997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003819469,0.000279154,0.7698607,0.00033507662,0.00060836266,0.0029436524,0.00076449825,0.000013784542,0.0014848589,0.001867576,0.011739454,0.20972095],"study_design_scores_gemma":[0.0025294311,0.005106102,0.0032211747,0.00008144885,0.000633705,0.00033232622,0.00004811348,0.04515448,0.0062650554,0.00025261083,0.9361228,0.00025279223],"about_ca_topic_score_codex":0.019238386,"about_ca_topic_score_gemma":0.11700789,"teacher_disagreement_score":0.9243833,"about_ca_system_score_codex":0.0035597687,"about_ca_system_score_gemma":0.002637685,"threshold_uncertainty_score":0.9890971},"labels":[],"label_agreement":null},{"id":"W4403962313","doi":"10.58931/cot.2024.1327","title":"Breast Cancer Survivorship","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Survivorship curve; Cancer survivorship; Breast cancer; Cancer; Oncology; Medicine; Internal medicine","score_opus":0.022832134160178454,"score_gpt":0.3269969300789985,"score_spread":0.30416479591882006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403962313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35189432,0.01844861,0.000031947435,0.28814378,0.008967322,0.0013088819,0.0011103784,0.0005665471,0.3295282],"genre_scores_gemma":[0.97599596,0.00057966006,0.00002545413,0.006213646,0.0010332193,0.00015086771,0.000030043126,0.000044705783,0.015926434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987096,0.00005212715,0.0001865411,0.00035180512,0.00012570701,0.0005741992],"domain_scores_gemma":[0.99890095,0.00013183706,0.000022128985,0.00016285306,0.00013466108,0.0006475823],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018818172,0.0001759701,0.00031001156,0.0003726671,0.00012821786,0.000022418477,0.00007386575,0.00021961426,0.004635707],"category_scores_gemma":[0.0000440636,0.00016245105,0.00009870317,0.000440287,0.00019993079,0.000066448345,0.000022610344,0.00042384543,0.00075666653],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001963498,0.0000727568,0.067190304,0.00024111626,0.0010370201,0.003917907,0.001224547,0.0000052691526,0.00020655409,0.0021297294,0.63391715,0.28986132],"study_design_scores_gemma":[0.00081408396,0.00029336053,0.18209234,0.000486992,0.00037327444,0.0014973388,0.0003372965,0.00012418545,0.000058754416,0.00021800722,0.813446,0.0002583755],"about_ca_topic_score_codex":0.23035215,"about_ca_topic_score_gemma":0.74549407,"teacher_disagreement_score":0.62410164,"about_ca_system_score_codex":0.0031869195,"about_ca_system_score_gemma":0.004296462,"threshold_uncertainty_score":0.9962742},"labels":[],"label_agreement":null},{"id":"W4409361702","doi":"10.58931/cot.2025.2131","title":"Clinical Considerations for the Management of Advanced PD-L1 ≥50% Non-small Cell Lung Cancer In 2025: Should All Patients Be Treated the Same?","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Lung cancer; Medicine; Intensive care medicine; Cancer; Oncology; Internal medicine","score_opus":0.04781192108716303,"score_gpt":0.3763830102409679,"score_spread":0.32857108915380484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409361702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82386047,0.00946243,0.00010718566,0.122450896,0.0029141554,0.010105205,0.0005808539,0.000029964302,0.030488854],"genre_scores_gemma":[0.9487644,0.0035166352,0.0006296555,0.037785422,0.00007907786,0.0011647098,0.00006164191,0.000024433939,0.007974054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987037,0.00008992559,0.0005292363,0.00026017215,0.00007756055,0.00033939],"domain_scores_gemma":[0.998485,0.000802457,0.00012373463,0.0003551998,0.000120870005,0.00011270904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004266228,0.000141882,0.0003477594,0.00013381822,0.00014848958,0.000009231816,0.00016044149,0.0001922381,0.00035913914],"category_scores_gemma":[0.000050727864,0.000094049356,0.00014675247,0.00023140373,0.00021419935,0.000022222752,0.00002614417,0.00023028118,0.0000012570945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052671833,0.00090066274,0.38415745,0.0008055039,0.0033785165,0.00010944177,0.0023120951,0.00041862126,0.00049486925,0.0010108263,0.36260888,0.23853597],"study_design_scores_gemma":[0.0136625655,0.0006563818,0.57734096,0.00065383926,0.0009689108,0.0000018575158,0.0013378082,0.00066589075,0.00036497493,0.00010866541,0.4040394,0.00019873884],"about_ca_topic_score_codex":0.03551166,"about_ca_topic_score_gemma":0.5729484,"teacher_disagreement_score":0.5374367,"about_ca_system_score_codex":0.0007836101,"about_ca_system_score_gemma":0.0017896469,"threshold_uncertainty_score":0.97091097},"labels":[],"label_agreement":null},{"id":"W4409361713","doi":"10.58931/cot.2025.2132","title":"Current Approaches and Future Directions for the Treatment of Solid Tumour Brain Metastases","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute; NRG Oncology; Breast Cancer Alliance","keywords":"Current (fluid); Medicine; Intensive care medicine; Oncology; Geology; Oceanography","score_opus":0.04357760434610908,"score_gpt":0.33419747797350463,"score_spread":0.29061987362739555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409361713","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15626508,0.34656233,0.001011683,0.47347036,0.0038726642,0.0077012894,0.0043249982,0.00008742984,0.006704167],"genre_scores_gemma":[0.9590715,0.022256434,0.004570728,0.0046745213,0.0015768089,0.002045634,0.0005610363,0.00005873102,0.0051845713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924856,0.00006987028,0.00017955744,0.00021202539,0.000044297947,0.00024566444],"domain_scores_gemma":[0.9990154,0.00046428415,0.000051461775,0.00021154014,0.000048687885,0.00020861576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001554999,0.00014130112,0.00036115551,0.00017132206,0.00021024984,0.000006380732,0.00004651551,0.00007126163,0.000055358603],"category_scores_gemma":[0.000048188333,0.000087177796,0.00013595854,0.00016125034,0.00014486958,0.00001576912,0.0000070168276,0.00006488216,0.0000015270555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010510719,0.00053423643,0.0011838909,0.00006545964,0.0008631203,0.000024769624,0.00063493487,0.000003970964,0.000022555081,0.009038579,0.029681822,0.9578416],"study_design_scores_gemma":[0.0019297167,0.0011485311,0.012767,0.000020933461,0.00095301936,0.00003508036,0.0010000218,0.000104238534,0.00028399169,0.00023741265,0.9814601,0.000059958227],"about_ca_topic_score_codex":0.005651543,"about_ca_topic_score_gemma":0.09266431,"teacher_disagreement_score":0.9577816,"about_ca_system_score_codex":0.0004630923,"about_ca_system_score_gemma":0.0010926299,"threshold_uncertainty_score":0.9238922},"labels":[],"label_agreement":null},{"id":"W4409361743","doi":"10.58931/cot.2025.2130","title":"The Role of ctDNA in Breast Cancer: Prognosis and Clinical Utility","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Breast cancer; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.007787703013319037,"score_gpt":0.297753369462649,"score_spread":0.28996566644933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409361743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97286123,0.009798798,0.0000032767027,0.007207276,0.00036221754,0.00022994317,0.00020164253,0.0000020347215,0.009333585],"genre_scores_gemma":[0.99324447,0.005512047,0.000030919324,0.000956281,0.00007777438,0.000036537524,0.000011239722,0.0000051081124,0.00012563796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992353,0.00006619721,0.00024158448,0.00021156322,0.000025674992,0.00021970796],"domain_scores_gemma":[0.9994591,0.00010094548,0.000051568564,0.00019268485,0.00006284465,0.00013286689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030632628,0.0000724704,0.00014925649,0.000043758155,0.00007304139,0.000009000761,0.00014906569,0.00020191596,0.000012709427],"category_scores_gemma":[0.00012790905,0.000063781896,0.000043046213,0.00008750273,0.00027025974,0.0000010822251,0.00006593042,0.00010778295,6.4947767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006714441,0.000032861255,0.74626064,0.0000049986234,0.000040502855,0.0000026082353,0.000014481866,0.000001961375,0.0005794827,0.0008504129,0.006021638,0.24612327],"study_design_scores_gemma":[0.00036787635,0.00007896254,0.5041639,0.0000117287655,0.000018317434,0.0000033895171,0.00010692784,0.00007666167,0.0008573508,0.0005125368,0.49374244,0.000059896392],"about_ca_topic_score_codex":0.05066136,"about_ca_topic_score_gemma":0.70761335,"teacher_disagreement_score":0.65695196,"about_ca_system_score_codex":0.0000972947,"about_ca_system_score_gemma":0.0021149053,"threshold_uncertainty_score":0.95566034},"labels":[],"label_agreement":null},{"id":"W4409362115","doi":"10.58931/cot.2025.2134","title":"Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Breast cancer; Adjuvant therapy; Medicine; Oncology; Adjuvant; Internal medicine; Cancer","score_opus":0.011886230167647342,"score_gpt":0.3271848254345535,"score_spread":0.3152985952669062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409362115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7795313,0.096911184,0.00060795376,0.049173817,0.0058396677,0.00449305,0.00964938,0.00006576742,0.053727873],"genre_scores_gemma":[0.97567165,0.016905203,0.0005723852,0.004883686,0.0004058425,0.0008772923,0.00027042828,0.00002676323,0.00038676654],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981255,0.00014460053,0.00034464445,0.0006237171,0.00004934125,0.0007122195],"domain_scores_gemma":[0.99894595,0.000069961774,0.00009292416,0.00033719672,0.000120734505,0.00043322696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003030906,0.00024019899,0.00043196653,0.00024975507,0.00022855037,0.000012951044,0.0002871578,0.00041116885,0.000036011654],"category_scores_gemma":[0.000079549696,0.00023115311,0.000115830546,0.00022431469,0.0002260575,0.00000733284,0.000030773645,0.00019482903,0.0000042108204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035683022,0.00010973933,0.4889355,0.000014886547,0.00021224575,0.000016404161,0.000067577115,0.00007508522,0.000024199479,0.000740635,0.021851337,0.48759556],"study_design_scores_gemma":[0.0033372354,0.00024371919,0.42559057,0.00002474906,0.00004923372,0.000012028719,0.00018446273,0.000024201177,0.00009256972,0.00040377906,0.56978893,0.00024847337],"about_ca_topic_score_codex":0.8011976,"about_ca_topic_score_gemma":0.9953799,"teacher_disagreement_score":0.54793763,"about_ca_system_score_codex":0.0009774492,"about_ca_system_score_gemma":0.006572753,"threshold_uncertainty_score":0.9990591},"labels":[],"label_agreement":null},{"id":"W4413382302","doi":"10.58931/cot.2025.2236","title":"Perioperative Treatment Strategies for Lung Cancer in 2025: A Paradigm Shift","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec - Clinical Research Organization in Cancer; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Perioperative; Paradigm shift; Intensive care medicine; Lung cancer; Cancer; Medicine; Oncology; Internal medicine; Anesthesia; Philosophy; Epistemology","score_opus":0.020118020745769693,"score_gpt":0.3727308848975044,"score_spread":0.3526128641517347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413382302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51976544,0.03350885,0.00019363617,0.29482427,0.0022250186,0.0076368437,0.00083098136,0.000087656765,0.1409273],"genre_scores_gemma":[0.98759705,0.00092774496,0.00013540163,0.0036431763,0.00012399338,0.0037480171,0.0000533511,0.000015624302,0.00375563],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890345,0.00003805254,0.00021359473,0.0003501663,0.000046316094,0.00044844532],"domain_scores_gemma":[0.99934214,0.00012185311,0.000032915465,0.0001971604,0.000033957,0.0002719717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006499598,0.00019155335,0.0004563965,0.0002716173,0.00011770771,0.000027474754,0.000061722225,0.00017100543,0.00047917303],"category_scores_gemma":[0.00001351126,0.00015764369,0.00009656342,0.00020585199,0.00007757299,0.000059432612,0.000007249814,0.0000953631,0.0000059982885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009893634,0.0012157733,0.59297,0.0004243992,0.0023590778,0.0015286918,0.011954558,0.00081078353,0.000058510086,0.22543645,0.056897912,0.10535446],"study_design_scores_gemma":[0.012850619,0.0022048682,0.22810759,0.00056598353,0.000755136,0.000011268738,0.0015404038,0.0011465445,0.0002677263,0.0015562485,0.7506744,0.00031919364],"about_ca_topic_score_codex":0.19688076,"about_ca_topic_score_gemma":0.92086875,"teacher_disagreement_score":0.723988,"about_ca_system_score_codex":0.010475351,"about_ca_system_score_gemma":0.013215977,"threshold_uncertainty_score":0.99332327},"labels":[],"label_agreement":null},{"id":"W4413382855","doi":"10.58931/cot.2025.2239","title":"Small-Cell Lung Cancer: Integration of Radiation and Immunotherapy for All Stages","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Immunotherapy; Lung cancer; Cancer; Medicine; Radiation therapy; Oncology; Cancer research; Internal medicine","score_opus":0.025115515050603034,"score_gpt":0.3782479123245323,"score_spread":0.35313239727392925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413382855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8067602,0.08449829,0.0015984224,0.07698238,0.001032477,0.00446659,0.00034038554,0.000054052176,0.024267225],"genre_scores_gemma":[0.97243094,0.011680221,0.00084320694,0.004717512,0.0001372753,0.0006216622,0.000075708376,0.00002181233,0.009471661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932665,0.000038508453,0.00017110878,0.00016652334,0.00005402365,0.0002432183],"domain_scores_gemma":[0.9993641,0.00016912831,0.000057207704,0.00013026217,0.00015186299,0.00012745317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021016975,0.00008711909,0.00026015384,0.000271972,0.00007415147,0.0000070072406,0.000060780883,0.00011196179,0.00005266319],"category_scores_gemma":[0.00011873806,0.000079929305,0.00003831639,0.00013193837,0.000102402366,0.000031529937,0.00001160318,0.000114466595,4.5488548e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006732643,0.00008622734,0.15731007,0.0007871922,0.0008531539,0.000018929231,0.0032887582,0.000012727802,0.032620497,0.002275824,0.18824475,0.6138286],"study_design_scores_gemma":[0.009390092,0.0015291414,0.17997049,0.000429374,0.00042795856,0.000005558492,0.0010772038,0.001146028,0.036143433,0.00045778265,0.769169,0.000253932],"about_ca_topic_score_codex":0.06419909,"about_ca_topic_score_gemma":0.2699619,"teacher_disagreement_score":0.6135747,"about_ca_system_score_codex":0.0014246607,"about_ca_system_score_gemma":0.0027098577,"threshold_uncertainty_score":0.9420325},"labels":[],"label_agreement":null},{"id":"W4413417222","doi":"10.58931/cot.2025.2235","title":"Antibody-Drug Conjugates in Breast Cancer: Current Landscape and Future Targets","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Mount Sinai Hospital","funders":"University of Toronto; University of Ottawa","keywords":"Antibody-drug conjugate; Breast cancer; Antibody; Drug; Conjugate; Medicine; Cancer; Cancer drugs; Current (fluid); Immunology; Cancer research; Pharmacology; Monoclonal antibody; Internal medicine; Engineering","score_opus":0.011839490796647313,"score_gpt":0.3703987486551005,"score_spread":0.35855925785845316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413417222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44610837,0.109995894,0.0000039729616,0.37715513,0.0038268054,0.0014466599,0.0005981013,0.000076431206,0.06078863],"genre_scores_gemma":[0.96647793,0.023093214,0.00007013705,0.0069221915,0.0011522225,0.00016761568,0.00015757377,0.00003394463,0.0019251544],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849105,0.00010061553,0.00023915918,0.00038429562,0.0001294365,0.0006554256],"domain_scores_gemma":[0.99888027,0.00008301622,0.00003424411,0.00024361529,0.00012326382,0.00063561846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031237234,0.00016660392,0.0004243012,0.00056230533,0.00010097163,0.000019978219,0.00014561698,0.00020291233,0.0012449612],"category_scores_gemma":[0.00003833567,0.00015640086,0.00003837007,0.00047439657,0.00018454164,0.000046864912,0.0000480125,0.0006482152,0.000030399146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008662782,0.000050889244,0.72646964,0.000223336,0.000042100084,0.00041874725,0.0004086522,0.0000014128545,0.00021806326,0.00062716834,0.12816128,0.14329208],"study_design_scores_gemma":[0.001199237,0.000041410072,0.34339133,0.00023204899,0.000023189305,0.000060333856,0.00029813452,0.000097331664,0.000038107828,0.00008959591,0.6544292,0.00010006948],"about_ca_topic_score_codex":0.070508465,"about_ca_topic_score_gemma":0.47181764,"teacher_disagreement_score":0.52626795,"about_ca_system_score_codex":0.0013070601,"about_ca_system_score_gemma":0.006786799,"threshold_uncertainty_score":0.99966806},"labels":[],"label_agreement":null},{"id":"W4413417257","doi":"10.58931/cot.2025.2237","title":"Treatment of Neuroendocrine Tumours: Approach of GEP-NETS","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Neuroendocrine tumors; Computer science; Internal medicine; Medicine","score_opus":0.025550826043837887,"score_gpt":0.3455222686199967,"score_spread":0.3199714425761588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413417257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7733224,0.0023944192,0.000014781941,0.016829133,0.0003487258,0.0013187974,0.00008979457,0.000041463885,0.20564048],"genre_scores_gemma":[0.9889077,0.00036870193,0.00088173803,0.00063946634,0.00004410547,0.00007639086,0.00003135698,0.00001970489,0.009030854],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984913,0.00010720951,0.00037069287,0.00031801473,0.00015690035,0.00055590866],"domain_scores_gemma":[0.99864817,0.00016102951,0.000097673685,0.00046155753,0.00015110234,0.00048046984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041428153,0.00017248034,0.00064769934,0.00066384836,0.00004415981,0.0000031643242,0.00017412464,0.000016014588,0.00015640628],"category_scores_gemma":[0.0002477485,0.000152244,0.00012300596,0.00045775465,0.0003242947,0.000039834144,0.00003146097,0.00015454309,0.00001078385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032098466,0.00680934,0.5109759,0.0019045018,0.0012994288,0.071287006,0.0005757606,0.00023911078,0.035621274,0.031178195,0.12851235,0.20838727],"study_design_scores_gemma":[0.008008115,0.009268731,0.082491316,0.000110248744,0.000294376,0.004340046,0.00050062616,0.0002465351,0.049558323,0.0004600151,0.8444871,0.00023459712],"about_ca_topic_score_codex":0.018266786,"about_ca_topic_score_gemma":0.034023765,"teacher_disagreement_score":0.71597475,"about_ca_system_score_codex":0.0006815952,"about_ca_system_score_gemma":0.0028993597,"threshold_uncertainty_score":0.98827064},"labels":[],"label_agreement":null},{"id":"W4413417272","doi":"10.58931/cot.2025.2238","title":"Management of Stage I–II Testicular Germ Cell Tumours: Current Treatment Paradigm and Future Perspectives","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Germ cell; Stage (stratigraphy); Current (fluid); Medicine; Cancer research; Biology; Engineering; Genetics","score_opus":0.00975194719520876,"score_gpt":0.29571720501908866,"score_spread":0.2859652578238799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413417272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8693026,0.09474737,0.00002017642,0.007606658,0.0004366123,0.0013451191,0.00024560236,0.000045644472,0.026250245],"genre_scores_gemma":[0.9930077,0.0033666336,0.00049411913,0.00016456636,0.000087690925,0.00008635596,0.000061611136,0.000014510921,0.0027167664],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99902165,0.00003932671,0.00018657882,0.00034365308,0.00008788832,0.00032092154],"domain_scores_gemma":[0.9990508,0.000035311583,0.00007571659,0.00029702432,0.000051353138,0.00048981037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004355083,0.00020390897,0.000365865,0.00021631541,0.00013700062,0.000008260559,0.00005980216,0.00009001942,0.00015383617],"category_scores_gemma":[0.00001017431,0.0001688186,0.0001033476,0.00017755004,0.00012927555,0.000025263018,0.000030142575,0.00008699529,0.000007985847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033648201,0.005482782,0.351609,0.0011322832,0.0019801692,0.010275522,0.0032770887,0.000019871763,0.000060232323,0.06699617,0.0051067756,0.55372363],"study_design_scores_gemma":[0.004766028,0.0015787054,0.59529823,0.00020516149,0.0018048795,0.000037347723,0.003140579,0.000047677375,0.000115073526,0.00033195695,0.3924866,0.00018777345],"about_ca_topic_score_codex":0.0043252623,"about_ca_topic_score_gemma":0.003933969,"teacher_disagreement_score":0.5535358,"about_ca_system_score_codex":0.001266859,"about_ca_system_score_gemma":0.0011387618,"threshold_uncertainty_score":0.68842226},"labels":[],"label_agreement":null},{"id":"W4415934922","doi":"10.58931/cot.2025.2342","title":"Original Research: Biomarker Testing in a Canadian Centre for Patients with Non‑small Cell Lung Cancer: Assessing Residual Risks","year":2025,"lang":"","type":"article","venue":"Canadian oncology today.","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Manitoba Health; Lunenfeld-Tanenbaum Research Institute; Occupational Cancer Research Centre; Public Health Ontario; University of Toronto; Toronto Public Health","funders":"","keywords":"ROS1; Erlotinib; Guideline; Biomarker; Lung cancer; Crizotinib; Epidermal growth factor receptor; Genetic testing; Cancer","score_opus":0.07447973931669052,"score_gpt":0.4308980292734839,"score_spread":0.35641828995679337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415934922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85087276,0.004305928,0.00003067566,0.023313476,0.0022807524,0.007182126,0.0019489679,0.000029608233,0.110035725],"genre_scores_gemma":[0.98466796,0.0001094712,0.00212483,0.0017672487,0.00033198416,0.0008010332,0.00044231818,0.00009674557,0.009658396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402463,0.00041259185,0.0007416886,0.0011435959,0.0003312804,0.003346225],"domain_scores_gemma":[0.9936405,0.0012668767,0.00022305244,0.00054926483,0.0016090714,0.0027112644],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0011015893,0.0005311355,0.0008231639,0.002950195,0.0014741002,0.00019682886,0.00038384908,0.00069520983,0.00043513702],"category_scores_gemma":[0.0007980825,0.00052238506,0.00008867,0.0025403048,0.0004184423,0.00022005546,0.000050606417,0.0010483017,0.000019631923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00024197822,0.00033215052,0.9086581,0.0004933279,0.00045587955,0.0008261606,0.0017229666,0.00010557488,0.000013462167,0.00014040842,0.04385665,0.04315336],"study_design_scores_gemma":[0.012950567,0.00093343784,0.67971885,0.0032192578,0.0013754007,0.000005918501,0.0025293822,0.00280167,0.000032132393,0.000057045214,0.29584518,0.0005311425],"about_ca_topic_score_codex":0.9907039,"about_ca_topic_score_gemma":0.99915123,"teacher_disagreement_score":0.25198853,"about_ca_system_score_codex":0.036539108,"about_ca_system_score_gemma":0.16275531,"threshold_uncertainty_score":0.99982584},"labels":[],"label_agreement":null},{"id":"W4415934991","doi":"10.58931/cot.2025.2343","title":"Current Issues in the Management of Sporadic Non-clear Cell Renal Cell Carcinoma (Non-ccRCC)","year":2025,"lang":"","type":"article","venue":"Canadian oncology today.","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Renal cell carcinoma; Kidney cancer; Cell; Clear cell renal cell carcinoma; Carcinoma; Cancer; Clear cell","score_opus":0.015709473236864595,"score_gpt":0.28532122771388924,"score_spread":0.2696117544770246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415934991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7118882,0.04306992,0.000017835748,0.0068138237,0.0020497704,0.0031320248,0.000083164436,0.000012134267,0.23293313],"genre_scores_gemma":[0.9776758,0.004465277,0.00031971952,0.0014750262,0.00032865943,0.00023679259,0.000110109024,0.00007028513,0.015318338],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.994203,0.000557687,0.0015650871,0.0012362004,0.0006027024,0.0018353753],"domain_scores_gemma":[0.99624527,0.00026879422,0.00047310683,0.0018132894,0.00020940602,0.0009901525],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012540383,0.00085508084,0.0015844244,0.0016041184,0.00029775675,0.000046932368,0.0012533492,0.00062434224,0.0010728015],"category_scores_gemma":[0.000018390363,0.00073719374,0.0004573851,0.0016581578,0.0006564268,0.00009626671,0.00022474935,0.001365393,0.00044712576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0030822163,0.00825204,0.26498947,0.015401125,0.0015659898,0.055857968,0.02612599,0.00030773773,0.002629457,0.0025333879,0.46520826,0.15404636],"study_design_scores_gemma":[0.010687814,0.0044872076,0.5196091,0.0018423245,0.0025626498,0.00005652643,0.009123395,0.00046869984,0.0078633055,0.00022754543,0.44229925,0.00077219907],"about_ca_topic_score_codex":0.096672095,"about_ca_topic_score_gemma":0.06414606,"teacher_disagreement_score":0.2657876,"about_ca_system_score_codex":0.005518809,"about_ca_system_score_gemma":0.006746188,"threshold_uncertainty_score":0.9998404},"labels":[],"label_agreement":null},{"id":"W4415935301","doi":"10.58931/cot.2025.2340","title":"Treatment of dMMR Metastatic Colorectal Cancer in 2025","year":2025,"lang":"","type":"article","venue":"Canadian oncology today.","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Colorectal cancer; Microsatellite instability; DNA mismatch repair; Immune system; Immune checkpoint; Cancer","score_opus":0.026955920441577165,"score_gpt":0.3520353368922473,"score_spread":0.3250794164506701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415935301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.846516,0.052590463,0.000009723589,0.0124082025,0.008054653,0.0027567532,0.0007390309,0.000019130312,0.07690606],"genre_scores_gemma":[0.97952086,0.0063252538,0.00027904482,0.0011650734,0.00018174658,0.000694968,0.00003165831,0.000046836685,0.011754542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585354,0.0004267086,0.0012076058,0.00086336845,0.00025618277,0.0013926179],"domain_scores_gemma":[0.99723244,0.00072421425,0.00027880294,0.0005549468,0.00029718157,0.0009124152],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002979534,0.00059472426,0.001857802,0.0016721097,0.0001245383,0.000014967049,0.00035677024,0.00067741104,0.008948608],"category_scores_gemma":[0.0003672295,0.00060339604,0.00028537033,0.0016870335,0.0007781226,0.00005092769,0.00005717286,0.00045378684,0.0000861755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023569083,0.0018166017,0.41519347,0.00075168244,0.0026851106,0.0026192789,0.0060597793,0.00087282324,0.0075223027,0.0014250053,0.020508448,0.5381886],"study_design_scores_gemma":[0.01956315,0.014922752,0.37923837,0.0014972338,0.0031513146,0.00008784435,0.0030235874,0.0021981054,0.02863649,0.0009054076,0.54573834,0.0010374124],"about_ca_topic_score_codex":0.41998035,"about_ca_topic_score_gemma":0.9365275,"teacher_disagreement_score":0.53715116,"about_ca_system_score_codex":0.021923514,"about_ca_system_score_gemma":0.04276146,"threshold_uncertainty_score":0.9996417},"labels":[],"label_agreement":null},{"id":"W4415935375","doi":"10.58931/cot.2025.2341","title":"First-line Treatment Selection for Advanced Unresectable Biliary Tract Cancer","year":2025,"lang":"","type":"article","venue":"Canadian oncology today.","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Biliary tract cancer; Biliary tract; Gallbladder cancer; Gallbladder; Cancer; Selection (genetic algorithm)","score_opus":0.030755536011891602,"score_gpt":0.3467443021864418,"score_spread":0.3159887661745502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415935375","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30951184,0.31138855,0.0007992597,0.2405775,0.02260074,0.013163286,0.0029309036,0.00027044353,0.098757476],"genre_scores_gemma":[0.9151184,0.01621613,0.00027379632,0.005792848,0.0015539745,0.0028479581,0.00013717193,0.000072852126,0.057986885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964832,0.000102057966,0.0006841696,0.0010330583,0.00014560924,0.0015518789],"domain_scores_gemma":[0.99740386,0.0006145604,0.00018383018,0.0004631373,0.0004574616,0.00087715563],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025371558,0.0006139477,0.0012641303,0.00079384015,0.0010523597,0.000038750357,0.00021495172,0.0006548069,0.001347766],"category_scores_gemma":[0.00027072107,0.0005977092,0.0004072336,0.00095365185,0.00025460534,0.00014343567,0.000035894136,0.0004115074,0.000039616134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002825618,0.0012009473,0.2118101,0.000946662,0.0034153215,0.00027430066,0.0026478935,0.0011558688,0.000666188,0.0007617734,0.21690297,0.55739236],"study_design_scores_gemma":[0.010994308,0.005212529,0.05212387,0.0005345034,0.001964511,0.00003465613,0.0007323406,0.0016078346,0.0013297491,0.00026136308,0.9247345,0.00046988306],"about_ca_topic_score_codex":0.31212345,"about_ca_topic_score_gemma":0.95193404,"teacher_disagreement_score":0.7078315,"about_ca_system_score_codex":0.01729657,"about_ca_system_score_gemma":0.017371254,"threshold_uncertainty_score":0.99964744},"labels":[],"label_agreement":null}]}